Investor Presentaiton

cendakimab (anti-IL-13) Indication Phase/Study Eosinophilic Esophagitis (EOE) Phase III CC-93538-EE-001 Oncology Hematology Cell Therapy Immunology Cardiovascular Eosinophilic Gastroenteritis (EGE) (Japan study) Phase III CC-93538-EG-001 - # of Patients Design Endpoints Status CT Identifier N = 399 Cendakimab 360 mg SC QW for 24 weeks, followed by 360 mg SC QW for 24 weeks Cendakimab 360 mg SC QW for 24 weeks, followed by 360 mg SC Q2W for 24 weeks Placebo for 48 weeks Primary: Change in Dysphagia Days (clinical response) at week 24 Eosinophil histologic response (≤ 6/hpf) at week 24 Expected data readout 2024 NCT04753697 • Cendakimab for 48 weeks • Placebo for 48 weeks N = 45 Primary: Eosinophil histologic response (change from baseline) at week 16 Key secondary: clinical response up to week 48 Expected data readout 2024 NCT05214768 ll Bristol Myers Squibb Q3 2023 Results Not for Product Promotional Use 47

View entire presentation